Publicacións en colaboración con investigadores/as de Fundación Jiménez Díaz (19)

2023

  1. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study

    European journal of preventive cardiology, Vol. 30, Núm. 4, pp. 320-328

2021

  1. Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study

    Atherosclerosis, Vol. 317, pp. 52-58

  2. Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience

    Journal of Clinical Lipidology, Vol. 15, Núm. 4, pp. 584-592

  3. Lipoprotein(a), LDL-cholesterol, and hypertension: Predictors of the need for aortic valve replacement in familial hypercholesterolaemia

    European Heart Journal, Vol. 42, Núm. 22, pp. 2201-2211

2020

  1. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry

    Revista Espanola de Cardiologia, Vol. 73, Núm. 10, pp. 828-834

2019

  1. Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study

    Journal of Clinical Lipidology, Vol. 13, Núm. 6, pp. 989-996

2018

  1. Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study

    Journal of Clinical Lipidology, Vol. 12, Núm. 4, pp. 948-957

2017

  1. Consecución de objetivos terapéuticos de colesterol LDL en niños y adolescentes con hipercolesterolemia familiar. Registro longitudinal SAFEHEART

    Revista Espanola de Cardiologia, Vol. 70, Núm. 6, pp. 444-450

  2. Predicting cardiovascular events in familial hypercholesterolemia: The SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study)

    Circulation, Vol. 135, Núm. 22, pp. 2133-2144

2016

  1. Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up

    Journal of the American College of Cardiology, Vol. 67, Núm. 11, pp. 1278-1285

  2. Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry

    Journal of Clinical Lipidology, Vol. 10, Núm. 4, pp. 953-961

  3. Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: Insights from the SAFEHEART registry (Spanish familial hypercholesterolaemia cohort study)

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 36, Núm. 9, pp. 2004-2010

  4. PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia

    Atherosclerosis, Vol. 254, pp. 249-253

2015

  1. Diagnóstico y tratamiento de la hipercolesterolemia familiar en España: Documento de consenso

    Atencion Primaria

2014

  1. Hiperlipidemia familiar combinada: documento de consenso

    Atencion Primaria, Vol. 46, Núm. 8, pp. 440-446

  2. Lipoprotein(a) levels in familial hypercholesterolemia: An important predictor of cardiovascular disease independent of the type of LDL receptor mutation

    Journal of the American College of Cardiology, Vol. 63, Núm. 19, pp. 1982-1989

2008

  1. Cardiovascular disease in familial hypercholesterolaemia: Influence of low-density lipoprotein receptor mutation type and classic risk factors

    Atherosclerosis, Vol. 200, Núm. 2, pp. 315-321

2005

  1. Screening of APOB gene mutations in subjects with clinical diagnosis of familial hypercholesterolemia

    Human Biology, Vol. 77, Núm. 5, pp. 663-673

2002

  1. Heterozygous familial hypercholesterolemia in Spain. Description of 819 non related cases

    Medicina Clinica, Vol. 118, Núm. 13, pp. 487-492